![Debra Stephanie Barker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Debra Stephanie Barker
Direttore/Membro del Consiglio presso
CUREVAC
Profilo
Debra Stephanie Barker is currently Non-Executive Director at CureVac SE, Senior Independent Non-Executive Director at Arix Bioscience Plc since 2022, Director at Hutman Diagnostics AG, Senior Independent Director at Arix Bioscience since 2022, and Member of the Supervisory Board at CureVac NV since 2022.
Former roles include Chief Executive Officer & Director at Destiny Pharma Plc in 2023, Non-Executive Director at Oncoinvent ASA, Head of Development for Anti-Infectives & Immunology at Novartis AG, and Chief Medical & Development Officer at Spexis Ltd. from 2017 to 2018.
Education includes graduate studies at King's College London and a doctorate from Queens' College Cambridge.
Posizioni attive di Debra Stephanie Barker
| Società | Posizione | Inizio |
|---|---|---|
| CUREVAC | Direttore/Membro del Consiglio | 22/06/2022 |
| ARIX BIOSCIENCE PLC | Direttore/Membro del Consiglio | 10/08/2022 |
Hutman Diagnostics AG
 Hutman Diagnostics AG Medical SpecialtiesHealth Technology Operates as an in vitro diagnostics product development and portfolio management company | Direttore/Membro del Consiglio | - |
CureVac SE
 CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies | Direttore/Membro del Consiglio | - |
Arix Bioscience /Venture Capital/
 Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience invests in companies located in the United Kingdom. The firm focuses on the therapeutics sector. It participates in early stage capital requirements. | Direttore/Membro del Consiglio | 01/08/2022 |
Precedenti posizioni note di Debra Stephanie Barker
| Società | Posizione | Fine |
|---|---|---|
| SPEXIS AG | Direttore Tecnico/Scientifico/R&S | 31/12/2018 |
| DESY PHAR | Amministratore Delegato | 01/09/2023 |
| ONCOINVENT ASA | Direttore/Membro del Consiglio | - |
| NOVARTIS AG | Corporate Officer/Principal | - |
Formazione di Debra Stephanie Barker
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
43
Relazioni di 1° grado
11
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 11 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology Develops tumor immunotherapies | Health Technology |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Spexis Ltd.
 Spexis Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that focuses on the discovery and development of macrocycle drugs addressing unmet medical needs | Health Technology |
King's College London
 King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Destiny Pharma Plc
 Destiny Pharma Plc Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops novel antimicrobial products | Health Technology |
BerGenBio ASA
 BerGenBio ASA Pharmaceuticals: MajorHealth Technology Develops drugs for aggressive, drug resistant cancers | Health Technology |
Queens' College Cambridge
 Queens' College Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Arix Bioscience Plc
 Arix Bioscience Plc Investment ManagersFinance Operates as a global venture capital firm | Finance |
Hutman Diagnostics AG
Hutman Diagnostics AG Medical SpecialtiesHealth Technology Operates as an in vitro diagnostics product development and portfolio management company | Health Technology |
CureVac NV
 CureVac NV BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops medicines based on messenger ribonucleic acid which includes prophylactic vaccines, oncology, and molecular therapies | Health Technology |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience invests in companies located in the United Kingdom. The firm focuses on the therapeutics sector. It participates in early stage capital requirements. | Finance |
